ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

Updated data for Blueprint's BLU-667 in RET-altered cancers presented Monday at the American Society of Clinical Oncology meeting in Chicago show that the compound could be competitive with fellow RET inhibitor LOXO-292 from Eli Lilly in RET-mutated

Read the full 377 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE